98%
921
2 minutes
20
Hexahydrocannabinol (HHC) is a phytocannabinoid that has been known since 1940, but has only recently appeared on the recreational drug market. For the analytical detection of HHC consumption, a GC-MS method for the quantification of cannabinoids was extended and validated by adding (9S)-HHC, (9 R)-HHC, (9S)-carboxy-HHC (HHC-COOH) and (9 R)-HHC-COOH. Both HHC and HHC-COOH epimers were chromatographically separated and the validation data were convincing for forensic toxicological routine analysis. This method was used to analyze 599 serum samples from forensic cases where cannabis use was suspected. Results were classified into three consumption groups: Δ-THC only (n = 574), Δ-THC and HHC (n = 19), and HHC only (n = 6). The concentration in serum was between 0.15 ng/mL to 14.4 ng/mL for (9 R)-HHC and 0.14 ng/mL to 5.76 ng/mL for (9S)-HHC. In all HHC positive samples, (9 R)-HHC-COOH could be detected in concentrations between 1.0 and 314 ng/mL. Of note, in the cases that tested positive for Δ-THC only, (9 R)-HHC-COOH was also unambiguously detected in serum samples as a metabolite not only of HHC but also of Δ-THC. In six urine samples of THC users that were examined by GC-MS and LC-MS/MS both epimers of HHC-COOH and their glucuronides could be detected. (9S)-HHC-COOH was the predominant epimer in urine which was not detected in serum. Results suggest that detection of HHC-COOH epimers alone cannot prove prior HHC consumption. With the data presented, we tentatively recommend a cut-off of 30 % of the (9 R)-HHC-COOH/THC-COOH ratio in serum to distinguish the intake of both substances from the intake of Δ-THC alone.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jpba.2025.116833 | DOI Listing |
Medication reconciliation was adopted as a National Patient Safety Goal by the Joint Commission in 2005 and is now standard practice across care settings. More recently, the concept of medication optimization has gained attention, recognizing that safe medication use requires more than reconciliation alone. Home healthcare (HHC) is one setting with a critical need for medication optimization.
View Article and Find Full Text PDFEur J Pharmacol
September 2025
Eisai, Inc., 200 Metro Blvd., Nutley, NJ, 07110, USA. Electronic address:
Phosphodiesterase 9 (PDE9) is an enzyme that hydrolyzes cyclic guanosine monophosphate (cGMP)-a second messenger that regulates neuronal plasticity and memory function. PDE9 inhibition has been shown to enhance cognitive function in rodents, underlining the potential of PDE9 inhibitors (PDE9Is) as novel therapeutics for cognitive dysfunction. Considering the critical role of nitric oxide (NO)-cGMP signaling cascade in acetylcholine (ACh) release, the combination of PDE9Is and acetylcholinesterase inhibitors may synergistically elevate ACh levels in the brain.
View Article and Find Full Text PDFAust J Gen Pract
September 2025
BSc (Hons), MSocHlth, PhD, Senior Research Fellow, Research and Development, Australian Red Cross Lifeblood, Melbourne, Vic; Honorary Senior Fellow, Melbourne School of Population and Global Health, The University of Melbourne, Vic.
Background And Objectives: Australian Red Cross Lifeblood (Lifeblood) provides therapeutic venesection for patients who meet evidence-based eligibility criteria. Many of these patients have iron overload due to hereditary haemochromatosis (HHC). This study aimed to gain knowledge into the demographic characteristics of donors with haemochromatosis and to investigate their knowledge, compliance and experiences with their condition.
View Article and Find Full Text PDFCureus
August 2025
Pathology and Laboratory Medicine, New York City Health and Hospitals Corporation (NYC HHC) Lincoln, Bronx, USA.
Dermatofibrosarcoma protuberans (DFSP) is a rare soft tissue sarcoma with a generally low risk for metastasis. Most individuals are diagnosed with this neoplasm in the third or fourth decade of life, with the growth usually being no larger than 5 cm in maximum diameter at the time of diagnosis. The majority of these patients are treated with wide local excision, with most experiencing no recurrence or metastasis.
View Article and Find Full Text PDFDrug Test Anal
September 2025
Institute of Forensic Medicine, Forensic Toxicology and Chemistry, University of Bern, Bern, Switzerland.
Tetrahydrocannabidiol (H4CBD) is an emerging semisynthetic cannabinoid, which has been known since 1940. Like hexahydrocannabinol (HHC), it is easily obtained by hydrogenation of available phytocannabinoids, in the case of H4CBD by hydrogenation of cannabidiol (CBD). H4CBD shows a weak affinity for the CB receptor, but it is unclear if H4CBD shows psychoactive properties, as reports from users are divided.
View Article and Find Full Text PDF